Chargement en cours...
Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia
The advent of novel immunotherapies, such as blinatumomab, inotuzumab, and chimeric antigen receptor (CAR) T cell therapy, has revolutionized the therapeutic landscape in the treatment of relapsed/refractory B cell acute lymphoblastic leukemia, but can be associated with specific toxicities. We revi...
Enregistré dans:
| Publié dans: | Ther Adv Hematol |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE Publications
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6971963/ https://ncbi.nlm.nih.gov/pubmed/32010436 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620719899897 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|